The association between mineralocorticoid receptor antagonist use and diabetes occurrence and progression: A systematic review and meta-analysis

Keyphrases

• Diabetes 100%
• Meta-analysis 100%
• Hemoglobin A1c (HbA1c) 100%
• Mineralocorticoid Receptor Antagonists 100%
• Spironolactone 100%
• Placebo 75%
• Finerenone 75%
• Diabetes Risk 50%
• Eplerenone 50%
• Glucose Level 50%
• Change from Baseline 50%
• No Significant Difference 25%
• Low Dose Rate 25%
• Adult Patients 25%
• Glucose-lowering Drugs 25%
• Glucose Metabolism 25%
• Head-to-head Comparison 25%
• New-onset Diabetes Mellitus 25%
• Clinical Indications 25%
• New-onset Diabetes 25%
• Glycemic Parameters 25%
• HbA1c Levels 25%
• Profile Changes 25%
• Insulin Initiation 25%
• Antagonist Activity 25%
• Use Profiles 25%
• Medication Classes 25%
• Glycemic Profile 25%
• Glycemic Benefits 25%
• Fasting Blood Glucose 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Hemoglobin A1c 100%
• Mineralocorticoid Antagonist 100%
• Glucose 100%
• Spironolactone 80%
• Placebo 60%
• Finerenone 60%
• Eplerenone 40%
• Diabetes Mellitus 20%
• Insulin 20%

Immunology and Microbiology

• Glucose Level 100%
• Glucose 100%
• Glucose Metabolism 50%
• Insulin 50%